ABL Completes Validation of New cGMP Manufacturing Facility
ROCKVILLE, MD (August 28, 2011) — Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.
The 72,000 square foot multi-product facility houses cGMP manufacturing suites and laboratory space for process development, preclinical testing, and basic research activities. The new facility is modular in design and utilizes disposable production systems in order to reduce change-over between products and increase operational flexibility and throughput. Segregated suites support the production of mammalian- and microbial-based therapeutics, viral-based vaccines and vectors, and aseptic filling of parenteral products.
Dr. Thomas VanCott, President and CEO of ABL commented, “This is a significant milestone for ABL and demonstrates our commitment to providing clients with state-of-the-art equipment and facilities coupled with our extensive scientific resources. We’ve passed several client-led quality audits of the facility and are delighted to begin client project work. ”
Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including various government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo models (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of four companies dedicated to developing translational science for better patient care globally.
For more information on ABL and our services, please visit our website at www.ablinc.com.